One of the most recurrent options is to target tumor vasculature, with several FDA-approved angiogenesis inhibitors available (see Table 2) such as bevacizumab (antibody directed against VEGF) or sorafenib and sunitinib, inhibitors of tyrosine kinase receptors (TKRs) that target multiple TKRs, including VEGF receptors (VEGFRs) and PDGF receptors (PDGFRs). The gene discussed is VEGFA; the disease is neoplasm.